Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

After adjusting for the weight loss benefits of surgery, GLP-1 drugs were linked to a 41% lower risk of obesity-related ...

Dr David Johnson discusses recent findings indicating that vitamin D deficiency may contribute to the development of various ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of ...

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

Liver damage, or cirrhosis, may cause no symptoms in its early stages. Early signs may be nonspecific, such as nausea or fatigue. Later stages can lead to symptoms such as jaundice, itchy skin ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income ...

A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease. Patients will be able to receive the ...

Dr. Stine is the recipient of multiple research grants and awards from the American Association for the Study of Liver Diseases and the American Cancer Society, and has maintained continuous ...